前列腺、肺、结直肠和卵巢癌筛查试验中用于子宫内膜癌早期检测的生物标志物组合
在美国前列腺、肺、结直肠和卵巢癌筛查试验(n=78,216)中开展巢式病例对照研究,纳入112例子宫内膜癌病例和112例对照,采用定量蛋白质组学和磷酸化蛋白质组学分析诊断前血清。由6种蛋白构成的整合风险评分区分病例与对照的曲线下面积为0.80(95%CI 0.72-0.88),但需验证该检测能否改善绝经后妇女子宫内膜癌的预测或检测。
要点
- 6种蛋白整合评分区分子宫内膜癌病例与对照的AUC为0.80(95%CI 0.72-0.88)。
- 血样采集至诊断平均3.5年(SD 1.9年),评分与采血距诊断时间相关。
- 作者指出需验证该检测能否改善绝经后妇女子宫内膜癌的预测或检测。
核心结论
- 使用前列腺、肺、结直肠和卵巢癌筛查试验诊断前血清构建的6种蛋白整合评分可区分绝经后子宫内膜癌病例与对照。
- 作者指出需验证该检测能否改善绝经后妇女子宫内膜癌的预测或检测。
研究设计与样本
- 在前列腺、肺、结直肠和卵巢癌筛查试验(n=78,216)的绝经后女性中开展巢式病例对照研究,纳入112例新发子宫内膜癌病例和112例对照。
- 诊断前血清经高丰度蛋白免疫去除后,采用压力循环技术及测序级猪胰蛋白酶消化。
- 采用高分辨率液相色谱-串联质谱和高度多重等压质量标签结合碱性反相液相色谱进行定量蛋白质组学和磷酸化蛋白质组学分析。
- 通过受试者工作特征曲线分析评估整合评分对癌症状态的预测能力。
主要发现
- 血样采集至子宫内膜癌诊断的平均时间为3.5年(SD 1.9年)。
- 病例与对照间有47种蛋白丰度存在差异(P < .05)。
- 通过回归分析筛选出高预测潜力的蛋白改变并汇总为整合评分。
- 6种蛋白的整合风险评分在采血距诊断≤2年、>2年且≤5年或>5年的病例中均与疾病发生率直接相关。
- 整合评分区分病例与对照的曲线下面积为0.80(95%置信区间0.72-0.88)。
局限性
- 作者指出需验证该检测能否改善绝经后妇女子宫内膜癌的预测或检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometrial cancer is the most common gynecological cancer in the United States. However, no early detection test exists for asymptomatic women at average risk for endometrial cancer. OBJECTIVE: We sought to identify early detection biomarkers for endometrial cancer using prediagnostic serum. STUDY DESIGN: We performed a nested case-control study of postmenopausal women in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial (n = 78,216), including 112 incident endometrial cancer cases and 112 controls. Prediagnostic serum was immunodepleted of high-abundance proteins and digested with sequencing grade porcine trypsin via pressure cycling technology. Quantitative proteomics and phosphoproteomics was performed using high-resolution liquid chromatography-tandem mass spectrometry and highly multiplexed isobaric mass tag combined with basic reversed-phase liquid chromatography. A set of proteins able to predict cancer status was identified with an integrated score assessed by receiver-operator curve analysis. RESULTS: Mean time from blood draw to endometrial cancer diagnosis was 3.5 years (SD, 1.9 years). There were 47 differentially abundant proteins between cases and controls (P < .05). Protein alterations with high predictive potential were selected by regression analysis and compiled into an aggregate score to determine the ability to predict endometrial cancer. An integrated risk score of 6 proteins was directly related to disease incidence in cases with blood draw ≤2 years, >2 years to ≤5 years or >5 years prior to cancer diagnosis. The integrated score distinguished cases from controls with an area under the curve of 0.80 (95% confidence interval, 0.72-0.88). CONCLUSION: An integrated score of 6 proteins using prediagnostic serum from the Prostate, Lung, Colorectal, and Ovarian cancer screening trial distinguishes postmenopausal endometrial cancer cases from controls. Validation is needed to evaluate whether this test can improve prediction or detection of endometrial cancer among postmenopausal women.
引用
- Tarney CM, Wang G, Bateman NW, et al. Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Am J Obstet Gynecol. 2019. PMID: 31279844. doi:10.1016/j.ajog.2019.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。